ArticleCytotechnology2013
Rational development of a serum-free medium and fed-batch process for a GS-CHO cell line expressing recombinant antibody.
Article in Cytotechnology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 82 citations in OpenAlex.
- Development of an HEK293 Suspension Cell Culture Medium, Transient Transfection Optimization Workflow, and Analytics for Batch rAAV Manufacturing.Biotechnology and bioengineering · 2025Article
- Destabilising Effect of Class B CpG Adjuvants on Different Proteins and Vaccine Candidates.Vaccines · 2025Article
- Improvement strategies for transient gene expression in mammalian cells.Applied microbiology and biotechnology · 2024Review
- Progress in fed-batch culture for recombinant protein production in CHO cells.Applied microbiology and biotechnology · 2023Review
- Modular development enables rapid design of media for alternative hosts.Biotechnology and bioengineering · 2022Article
- Review
- Compartment-specificEngineering in life sciences · 2021Article
- Impact of iron raw materials and their impurities on CHO metabolism and recombinant protein product quality.Biotechnology progress · 2021Article
- Trends in Monoclonal Antibody Production Using Various Bioreactor Syst.Journal of microbiology and biotechnology · 2021Review
- Digital Twins and Their Role in Model-Assisted Design of Experiments.Advances in biochemical engineering/biotechnology · 2021Article
- Serum-Free Medium for Recombinant Protein Expression in Chinese Hamster Ovary Cells.Frontiers in bioengineering and biotechnology · 2021Review
- Methylthioadenosine (MTA) boosts cell-specific productivities of Chinese hamster ovary cultures: dosage effects on proliferation, cell cycle and gene expression.FEBS open bio · 2020Article
- A novel method based on nonparametric regression with a Gaussian kernel algorithm identifies the critical components in CHO media and feed optimization.Journal of industrial microbiology & biotechnology · 2020Article
- Early integration of Design of Experiment (DOE) and multivariate statistics identifies feeding regimens suitable for CHO cell line development and screening.Cytotechnology · 2019Article
- An efficient protein production system via gene amplification on a human artificial chromosome and the chromosome transfer to CHO cells.Scientific reports · 2019Article
- A statistical approach to improve compound screening in cell culture media.Engineering in life sciences · 2019Article
- The enhancement of antibody concentration and achievement of high cell density CHO cell cultivation by adding nucleoside.Cytotechnology · 2017Article
- A simultaneous assessment metric for MAb quantity and glycan quality.Cytotechnology · 2016Article
- Amino acid consumption in naïve and recombinant CHO cell cultures: producers of a monoclonal antibody.Cytotechnology · 2015Article
- Design of serum-free medium for suspension culture of CHO cells on the basis of general commercial media.Cytotechnology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A serum-free medium (CHO-SFM) together with a fed-batch process was developed for the cultivation of a recombinant GS-CHO cell line producing TNFR-Fc. According to the metabolic characteristics of GS-CHO cell, a basal medium was prepared by supplementing DMEM:F12:RPMI1640 (2:1:1) with amino acids, insulin, transferrin, Pluronic F68 and some other ingredients. Statistical optimization approaches based on Plackett-Burman and central composite designs were then adopted to identify additional positive determinants and determine their optimal concentrations, which resulted in the final CHO-SFM medium formulations. The maximum antibody titer reached was 90.95 mg/l in the developed CHO-SFM, which was a 18 % and 10 fold higher than that observed in the commercial EX-CELL™ 302 medium (76.95 mg/l) and basal medium (8.28 mg/l), respectively. Subsequently, a reliable, reproducible and robust fed-batch strategy was designed according to the offline measurement of glucose, giving a final antibody yield of 378 mg/l, which was a threefold improvement over that in conventional batch culture (122 mg/l) using CHO-SFM. In conclusion, the use of design of experiment (DoE) method facilitated the development of CHO-SFM medium and fed-batch process for the production of recombinant antibody using GS-CHO cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.